---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-118368"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:15:49.814333+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25

## Summary
- Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.
- Lead programs: first-in-class anti-IL-38 mAb and FAP-targeted radioligand therapy (177Lu-FAP).
- IND filing for 177Lu-FAP anticipated in Q1 2025; preclinical data show single-dose antitumor activity.
- Pipeline includes ADC strategy centered on novel targets; 70 antibody-target pairs identified to date.
- Management team led by former Seagen CEO Clay Siegall; headquarters in Bothell, WA.

## SEC filing metadata
- accession: 0001104659-23-118368
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/0001104659-23-118368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465923118368/tm2330767d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-118368
- JSON: https://secwatch.observer/filing/0001104659-23-118368.json
- Plain text: https://secwatch.observer/filing/0001104659-23-118368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.